False, misleading or fraudulent claims have long brought the wrath of juries, judges and government agencies down on perpetrators. So have substandard manufacturing practices.

  • GlaxoSmith Klein has agreed to plead guilty and pay a $750-million fine for manufacturing deficiencies at a former pharmaceuticals plant. Even though there was no indication of patient harm, said the US attorney, the fine was needed “to pressure companies to follow the rules.”
  • Johnson & Johnson was recently slapped with a $258-million jury verdict for allegedly misleading claims about the safety and superiority of an antipsychotic drug. J&J’s actions “defrauded the Louisiana Medicaid system,” prosecutors argued. (The c